You might want to take a look at Cardiff Oncology Inc (CRDF) now

With 0.83 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.23 million shares. The 52-week range on CRDF shows that it touched its highest point at $6.42 and its lowest point at $2.01 during that stretch. It currently has a 1-year price target of $14.25. Beta for the stock currently stands at 1.65.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRDF was up-trending over the past week, with a rise of 0.66%, but this was down by -16.88% over a month. Three-month performance surged to 59.34% while six-month performance rose 73.76%. The stock lost -1.29% in the past year, while it has lost -11.52% so far this year. A look at the trailing 12-month EPS for CRDF yields -0.95 with Next year EPS estimates of -0.95. For the next quarter, that number is -0.19. This implies an EPS growth rate of 16.14% for this year and -19.50% for next year. EPS is expected to decline by -7.72% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 19.36%.

Float and Shares Shorts:

At present, 66.52 million CRDF shares are outstanding with a float of 59.79 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRDF since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.92823 being high and -$1.02804 being low. For CRDF, this leads to a yearly average estimate of -$0.98812. Based on analyst estimates, the high estimate for the next quarter is -$0.18 and the low estimate is -$0.22. The average estimate for the next quarter is thus -$0.2.